Mirati Therapeutics joins Cancer Research UK’s Stratified Medicine Programme

Cancer Research UK

Mirati Therapeutics, Inc. is the latest partner of Cancer Research UK’s Stratified Medicine Programme, bringing new investigational treatment options to eligible patients with advanced lung cancer, through the National Lung Matrix Trial.

The partnership, announced today (Tuesday), will make Mirati’s experimental drug, sitravatinib, available for inclusion in the programme.

“This partnership exemplifies the flexible approach of Cancer Research UK’s Stratified Medicine Programme and the National Lung Matrix Trial, to improve our understanding and accelerate progress in treating lung cancer.”Dr Ian Walker, Cancer Research UK

Sitravatinib targets genetic vulnerabilities* that are collectively found in around 5.5% of non-small cell lung cancer patients (NSCLC) and could offer a new, more effective, treatment option for some lung cancer patients.

Dr Ian Walker, director of clinical, population and early detection research at Cancer Research UK, said: “We’re delighted that Mirati is making their investigational drug for lung cancer available to the Stratified Medicine Programme. By working together, we’re adapting and shifting the emphasis of clinical trials from focusing on the same therapy for all patients, to designing drugs around specific patients, paving the way to an era of precision medicine.

“This partnership exemplifies the flexible approach of Cancer Research UK’s Stratified Medicine Programme and the National Lung Matrix Trial, to improve our understanding and accelerate progress in treating lung cancer.”

The adaptive and evolving approach of Cancer Research UK’s Stratified Medicine Programme** and its associated precision medicine phase II trial, the National Lung Matrix Trial, allows new research questions to be addressed in a timely manner with new arms introduced and others closed as required. The trial has been renewed for another 3 years and recently marked the recruitment of its 250th patient.

Under the terms of the deal, Mirati will provide sitravatinib, to be tested in three arms of the trial, in addition to financial support for the Stratified Medicine Programme.  

Charles M. Baum, M.D., Ph.D., Mirati’s president and chief executive officer, said: “The design and scope of the Stratified Medicine Programme provides an exceptional opportunity for clinical research. We are excited to partner with Cancer Research UK and honoured to have sitravatinib selected to be a part of this innovative trial.”

ENDS

For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.

Notes to Editor

*Genetic alterations involving RET gene rearrangements, CHR4q12 amplifications, and CBL mutations.

**The Stratified Medicine Programme is a collaboration between Cancer Research UK and the Experimental Cancer Medicine Centres, the NHS, University of Birmingham Cancer Research Clinical Trials Unit, Illumina, Astra Zeneca and Pfizer. It was the first national study of its kind in the UK to pre-screen patients for their molecular eligibility for a cancer clinical trial. Excess diagnostic biopsy tissue from patients with advanced lung cancer is screened for specific markers to assess the likelihood of a targeted treatment being effective for each patient.

Its associated precision medicine phase II trial, the National Lung Matrix Trial, consists of over 20 different biomarker-drug combination cohorts and uses a design that allows the trial to adapt and evolve as necessary. This trial is sponsored by the University of Birmingham Cancer Research UK Clinical Trials Unit. 

About Sitravatinib

Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including  TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. As an immuno-oncology agent, sitravatinib is being evaluated in combination with checkpoint inhibitors. A phase 2 clinical trial is currently evaluating the combination of sitravatinib and a check point inhibitor in patients with non-small cell lung cancer who have experienced documented disease progression following prior treatment with a checkpoint inhibitor.

Sitravatinib is also being evaluated as a single agent in a Phase 1b expansion clinical trial in patients with non-small cell lung cancer and other tumor types who have specific genetic alterations in CBL, CHR4Q12 and RET.

About Mirati Therapeutics

Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. Our precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who we believe would be most likely to benefit from targeted drug treatment. In immuno-oncology, we are advancing clinical programs where our product candidates have the potential to improve the immune environment of tumor cells and may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. Our pre-clinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. We approach each of our discovery and development programs with a singular focus: to translate our deep understanding of the molecular drivers of cancer into better therapies and better outcomes for patients. For more information, visit www.mirati.com.